RecruitingNot ApplicableNCT07082595

Personalized Stimulation Loop for Neurorehabilitation in Parkinson: a Proof-of-principle Study


Sponsor

University of Zurich

Enrollment

40 participants

Start Date

Jul 7, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Parkinson's disease (PD) is a neurodegenerative disease that affects about 1% of the elderly population and accounts for substantial disability and health care costs. Disability is largely driven by mobility deficits caused by impaired gait. Effective treatments are available to restore lower limb function and improve gait, but response to treatment varies greatly from patient to patient and often shows only small effect sizes. Addressing this heterogeneity requires personalization, a concept referred to precision neurorehabilitation. StimuLOOP.PD-Sleep intends to foster structured and reproducible methods for precision neurorehabilitation of gait in PD. The investigators will conduct a proof-of-concept study to investigate a sleep intervention tailored to the individual patient in the context of motor rehabilitation. • Targeted auditory stimulation during sleep (TASS): The investigators aim to reactive rehabilitation-related memories through presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands. The investigators will leverage TASS to enhance consolidation of the movement patterns that are learned during rehabilitation. The investigators expect that this intervention will lead to greater gains in functional walking ability and balance. Beyond demonstrating a proof-of-concept for novel methods of applying TASS stimulation in the context of neurorehabilitation, positive results of this project may have implications for neurorehabilitation treatment in general by providing first insights into the benefits and interplay of TASS with a rehabilitation.


Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Idiopathic Parkinson's disease with gait and postural stability deficits
  • ≥18 years of age
  • UPDRS III gait scores 1-3
  • UPDRS III postural instability scores 1-3
  • Prescribed rehabilitation therapy
  • Informed consent as documented by signature
  • Adjustments in dopaminergic medication and DBS stimulation to improve

Exclusion Criteria8

  • Cognitive impairment, Montreal Cognitive Assessment (MoCa) \< 20
  • Other neurological or medical condition that caused sustained clinically relevant gait and/or postural stability deficits
  • History of a physical or neurological condition that interferes with study procedures
  • Social and/or personal circumstances that interfere with the ability to return for assessments
  • Patients taking benzodiazepines or Z-drugs that have a significant effect on sleep EEG
  • Recent DBS implant (≤ 6 months)
  • Inability to perform outcome assessments without walking aid
  • Skin disorders/problems/allergies in face/ear area that could worsen with electrode application (e.g. nickel allergy)

Interventions

OTHERTASS Intervention (Sham)

Participants will sleep with the portable EEG (TSB, Axo, Tosoo AG, Zurich, CH) during 15 days of their regular motor rehabilitation. No auditory stimuli will be delivered.

OTHERTASS Intervention (Verum)

TASS: Participants will sleep with the portable EEG (TSB, Axo, Tosoo AG, Zurich, CH) during 15 days of their regular motor rehabilitation. Auditory stimuli will be delivered through the integrated headphones when non-rapid-eye-movement (NREM) sleep is detected during the night to induce TASS.


Locations(1)

University of Zurich

Zurich, Canton of Zurich, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07082595


Related Trials